Innotox 100iu

Innotox represents a breakthrough in neuromodulator technology as the first commercially available liquid-phase botulinum toxin type A (BTX-A). Utilizing Medytox’s patented stabilization technology (KR Patent No. 1020150034567), this premixed solution eliminates reconstitution errors and maintains 99.3% neurotoxin potency at 4°C for 24 months. The formulation contains 100U of highly purified 900kDa BTX-A complex with <2pg of endotoxin per vial, meeting stringent USP <85> standards for parenteral preparations.

Product Specifications

• Active Substance: Botulinum Toxin Type A 100U/vial
• Formulation: Ready-to-use liquid (pH 6.8±0.3)
• Preservative: 0.9% sodium chloride, 0.05% polysorbate 20
• Storage: 2-8°C protected from light
• Shelf Life: 24 months unopened
• Dilution: Not required (premixed solution)
• Administration: IM injection using 30-32G needle
• Dosing: 2-4U per injection point (glabellar complex)
• Max Dose: 100U per treatment session
• Treatment Interval: ≥12 weeks